2016 Press Releases

September 26, 2016 at 9:00 a.m. ETIdera Pharmaceuticals, Inc. Corporate Conference Call
November 16, 2016 at 3:00 p.m. ETIdera Pharmaceuticals, Inc. at Stifel 2016 Healthcare Conference
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
Nov 28, 2016Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200Read MoreNov 11, 2016Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 TreatmentRead MoreNov 10, 2016Idera to Present at the Stifel 2016 Healthcare ConferenceRead MoreNov 09, 2016Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual MeetingRead MoreOct 28, 2016Idera Pharmaceuticals Reports Third Quarter 2016 Financial ResultsRead MoreOct 07, 2016Idera Pharmaceuticals Announces Pricing of Public Offering of Common StockRead MoreOct 05, 2016Idera Pharmaceuticals Announces Proposed Public Offering of Common StockRead MoreSep 27, 2016Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics SocietyRead MoreSep 26, 2016Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic MelanomaRead MoreAug 24, 2016Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense TechnologyRead MoreAug 12, 2016Idera to Present at the 2016 Wedbush PacGrow Healthcare ConferenceRead MoreAug 02, 2016Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate UpdateRead MoreJun 07, 2016Idera to Present at Two June Investor Healthcare ConferencesRead MoreMay 09, 2016Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate UpdateRead MoreMay 05, 2016Idera to Release 2016 First Quarter Results on May 9, 2016Read MoreApr 19, 2016Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016Read MoreApr 11, 2016Idera to Present at the 15th Annual Needham Healthcare ConferenceRead MoreMar 10, 2016Idera Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Provides Corporate UpdateRead MoreMar 03, 2016Idera to Present at Two March Investor Healthcare ConferencesRead MoreJan 06, 2016Idera Pharmaceuticals Announces Appointment of Dr. Maxine Gowen to Its Board of DirectorsRead MoreJan 05, 2016Idera to Present at the 34th Annual J.P. Morgan Healthcare ConferenceRead More